{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:52:21Z","timestamp":1791298341286,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is unknown whether the severity, timing, and quality of graft-versus-host disease (GVHD) may be different after nonmyeloablative as compared with myeloablative hematopoietic stem cell transplantation (HSCT). Therefore, GVHD incidence, morbidity of skin, liver, and gut, requirements for immunosuppressive therapy, and survival were retrospectively analyzed in 44 patients who underwent nonablative HSCT and 52 who underwent ablative HSCT (median ages, 56 and 54 years, respectively). The nonablative transplantation regimen consisted of low-dose total body irradiation (TBI), preceded in some patients by fludarabine administration and followed in all patients by immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP). Those who underwent myeloablative HSCT were prepared with different TBI- and non-TBI\u2013containing regimens and received CSP plus methotrexate or MMF for GVHD prophylaxis. The cumulative incidence of grades II-IV acute GVHD was lower after nonablative transplantation (64% vs 85%; P = .001), but there were no differences in the cumulative incidence of chronic GVHD requiring treatment (73% vs 71%; P = .96). Nonablative transplantation was associated with the delayed initiation of steroid treatment for GVHD (0.95 months vs 3.0 months; P &amp;lt; .001) and with the use of fewer systemic immunosuppressants in the first 3 months after transplantation (P \u2264 .04). This corresponded to more prevalent skin and more severe gut morbidity 6 to 12 months after nonablative transplantation. Our results show that nonablative HSCT is associated with a syndrome of acute GVHD occurring after day 100 in many patients. This \u201clate-onset acute GVHD\u201d should be taken into consideration in the design of prospective studies comparing GVHD resulting from the two types of transplantation procedures.<\/jats:p>","DOI":"10.1182\/blood-2002-08-2628","type":"journal-article","created":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T01:26:35Z","timestamp":1049160395000},"page":"756-762","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":484,"title":["Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"102","author":[{"given":"Marco","family":"Mielcarek","sequence":"first","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Martin","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Leisenring","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E. D.","family":"Flowers","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"From the Divisions of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Research Center; and the Departments of Medicine and Biostatistics, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300100184100_REF1","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97: 3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021300100184100_REF2","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91: 756-763.","DOI":"10.1182\/blood.V91.3.756"},{"key":"2020021300100184100_","unstructured":"Sandmaier BM, Maloney DG, Gooley T, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen [abstract]. Blood. 2001;98(part 1): 742."},{"key":"2020021300100184100_REF4","unstructured":"Maris M, Niederwieser D, Sandmaier B, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10\/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT [abstract]. Blood. 2001;98(part 1): 858."},{"key":"2020021300100184100_","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Ko\u0308rbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol.1998;16: 2817-2824.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2020021300100184100_REF6","doi-asserted-by":"crossref","unstructured":"Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97: 631-637.","DOI":"10.1182\/blood.V97.3.631"},{"key":"2020021300100184100_REF7","doi-asserted-by":"crossref","unstructured":"Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89: 4531-4536.","DOI":"10.1182\/blood.V89.12.4531"},{"key":"2020021300100184100_REF8","doi-asserted-by":"crossref","unstructured":"Mielcarek M, Sandmaier BM, Maloney DG, et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol.2002;22: 70-74.","DOI":"10.1023\/A:1014532401666"},{"key":"2020021300100184100_REF9","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98: 3595-3599.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"2020021300100184100_REF10","doi-asserted-by":"crossref","unstructured":"Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99: 1071-1078.","DOI":"10.1182\/blood.V99.3.1071"},{"key":"2020021300100184100_REF11","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia [review]. Blood. 1995;86: 813-818.","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813"},{"key":"2020021300100184100_REF12","doi-asserted-by":"crossref","unstructured":"Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18: 295-304.","DOI":"10.1097\/00007890-197410000-00001"},{"key":"2020021300100184100_REF13","doi-asserted-by":"crossref","unstructured":"Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75: 1024-1030.","DOI":"10.1182\/blood.V75.4.1024.1024"},{"key":"2020021300100184100_REF14","unstructured":"Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol.1991;28: 250-259."},{"key":"2020021300100184100_REF15","doi-asserted-by":"crossref","unstructured":"Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90: 3204-3213.","DOI":"10.1182\/blood.V90.8.3204"},{"key":"2020021300100184100_REF16","doi-asserted-by":"crossref","unstructured":"Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review]. Blood. 2000;95: 2754-2759.","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759"},{"key":"2020021300100184100_","doi-asserted-by":"crossref","unstructured":"Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest.1998;102: 1882-1891.","DOI":"10.1172\/JCI4285"},{"key":"2020021300100184100_REF18","doi-asserted-by":"crossref","unstructured":"Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor \u03b1 during graft-versus-host disease. J Exp Med.1992;175: 405-413.","DOI":"10.1084\/jem.175.2.405"},{"key":"2020021300100184100_REF19","doi-asserted-by":"crossref","unstructured":"Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83: 2360-2367.","DOI":"10.1182\/blood.V83.8.2360.2360"},{"key":"2020021300100184100_REF20","doi-asserted-by":"crossref","unstructured":"Colson YL, Lange J, Fowler K, Ildstad ST. Mechanism for cotolerance in nonlethally conditioned mixed chimeras: negative selection of the V\u03b2 T-cell receptor repertoire by both host and donor bone marrow-derived cells. Blood. 1996;88: 4601-4610.","DOI":"10.1182\/blood.V88.12.4601.bloodjournal88124601"},{"key":"2020021300100184100_REF21","doi-asserted-by":"crossref","unstructured":"Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation. 1998;66: 96-102.","DOI":"10.1097\/00007890-199807150-00015"},{"key":"2020021300100184100_REF22","doi-asserted-by":"crossref","unstructured":"Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94: 3234-3241.","DOI":"10.1182\/blood.V94.9.3234"},{"key":"2020021300100184100_REF23","doi-asserted-by":"crossref","unstructured":"Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285: 412-415.","DOI":"10.1126\/science.285.5426.412"},{"key":"2020021300100184100_REF24","doi-asserted-by":"crossref","unstructured":"Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med.2002;8: 575-581.","DOI":"10.1038\/nm0602-575"},{"key":"2020021300100184100_REF25","doi-asserted-by":"crossref","unstructured":"Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med.1986;314: 729-735.","DOI":"10.1056\/NEJM198603203141201"},{"key":"2020021300100184100_REF26","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant.1995;15: 825-828."},{"key":"2020021300100184100_REF27","doi-asserted-by":"crossref","unstructured":"Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100: 48-51.","DOI":"10.1182\/blood.V100.1.48"},{"key":"2020021300100184100_REF28","doi-asserted-by":"crossref","unstructured":"Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88: 4063-4071.","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063"},{"key":"2020021300100184100_REF29","doi-asserted-by":"crossref","unstructured":"Marr KA, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96: 2055-2061.","DOI":"10.1182\/blood.V96.6.2055"},{"key":"2020021300100184100_REF30","doi-asserted-by":"crossref","unstructured":"Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis.1998;27: 191-204.","DOI":"10.1086\/514626"},{"key":"2020021300100184100_REF31","doi-asserted-by":"crossref","unstructured":"Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99: 1978-1985.","DOI":"10.1182\/blood.V99.6.1978"},{"key":"2020021300100184100_REF32","unstructured":"Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980."},{"key":"2020021300100184100_REF33","doi-asserted-by":"crossref","unstructured":"Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80: 1838-1845.","DOI":"10.1182\/blood.V80.7.1838.1838"},{"key":"2020021300100184100_REF34","doi-asserted-by":"crossref","unstructured":"Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51: 1197-1203.","DOI":"10.1097\/00007890-199106000-00010"},{"key":"2020021300100184100_REF35","unstructured":"Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant.1989;4: 247-254."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/2\/756\/1688828\/h81403000756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/2\/756\/1688828\/h81403000756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T08:15:31Z","timestamp":1584519331000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/2\/756\/17401\/Graftversushost-disease-after-nonmyeloablative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-08-2628","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,15]]}}}